Unveiling Walgreens (WBA) Q3 Outlook: Wall Street Estimates for Key Metrics

Walgreens Boots Alliance (WBA) is anticipated to report Q3 earnings of $0.34 per share, marking a 46% year-over-year decline, despite projected revenues of $36.66 billion, a 0.9% increase. Analysts forecast a significant drop in U.S. Retail Pharmacy adjusted operating income to $113.67 million from $501 million a year ago, while International operating income is expected to rise slightly. The consensus EPS estimate has held steady for 30 days, and WBA shares have recently outperformed the broader market, gaining 1.3% in the past month, earning a Zacks Rank #2 (Buy) expectation for continued outperformance.

Analysis

Walgreens Boots Alliance (WBA) faces a challenging outlook for its upcoming Q3 report, with consensus estimates pointing to a significant profitability contraction despite modest top-line growth. Analysts forecast a 46% year-over-year decline in earnings per share to $0.34, while revenue is expected to increase by a marginal 0.9% to $36.66 billion. The primary source of this margin erosion is concentrated in the core U.S. Retail Pharmacy segment, where adjusted operating income is projected to plummet to $113.67 million from $501 million in the prior-year period. While the smaller U.S. Healthcare segment is expected to grow revenue by 2.3% and the International segment is forecasted to see a slight increase in operating income to $196.39 million, these improvements are insufficient to offset the severe pressure in the company's largest division. Despite these grim fundamental forecasts, which have remained stable for the last 30 days, WBA's stock has outperformed the S&P 500 composite over the past month (+1.3% vs +0.5%) and holds a Zacks Rank #2 (Buy), creating a notable divergence between underlying business performance and near-term market expectations.

Key Decisions for Investors

• Investors should scrutinize management's commentary during the earnings call for specific details on the drivers of the severe margin compression in the U.S. Retail Pharmacy segment and any actionable plans to restore profitability.
• Given the conflict between the negative fundamental outlook and the positive Zacks rating, traders may consider the possibility that the poor results are already priced in, but long-term investors should remain cautious until there is clear evidence of a turnaround in core operating income.
• Monitor the performance of the U.S. Healthcare and International segments closely, as outperformance in these areas will be critical to offsetting the structural weakness in the core U.S. retail business and justifying a more constructive long-term thesis.